Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 2/20 | 0.62 |
| ▸ | SYK | P43405 | 2/20 | 0.62 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.62 |
| ▸ | FES | P07332 | 1/20 | 0.62 |
| ▸ | FER | P16591 | 1/20 | 0.62 |
| ▸ | FRK | P42685 | 1/20 | 0.62 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.62 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.62 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 8/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | SMG1 | Q96Q15 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL303142 | 1.00 | TYK2 (0.62) | TYK2SYKIRAK4FESFER | |
| SCHEMBL13759349 | 0.92 | TYK2 (0.51) | TYK2SYKIRAK4FESFER | |
| SCHEMBL429472 | 0.90 | TYK2 (0.73) | TYK2SYKIRAK4FESFER | |
| SCHEMBL429471 | 0.90 | TYK2 (0.73) | TYK2SYKIRAK4FESFER | |
| SCHEMBL424652 | 0.89 | TYK2 (0.61) | TYK2SYKIRAK4FESFER | |
| SCHEMBL424653 | 0.89 | TYK2 (0.61) | TYK2SYKIRAK4FESFER | |
| SCHEMBL430479 | 0.89 | TYK2 (0.61) | TYK2SYKIRAK4FESFER | |
| SCHEMBL430480 | 0.89 | TYK2 (0.61) | TYK2SYKIRAK4FESFER | |
| SCHEMBL302443 | 0.87 | TYK2 (0.64) | TYK2SYKIRAK4FESFER | |
| SCHEMBL302444 | 0.87 | TYK2 (0.64) | TYK2SYKIRAK4FESFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4851337-B2 | — | — | 2012-01-11 | — | — | JP | claimed |
| US-7935698-B2 | Heteroaryl-hydrazone compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-05-03 | — | — | US | claimed |
| EP-1689403-A4 | HETEROARYL-HYDRAZONE COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2007-09-05 | — | — | EP | claimed |
| JP-2007510748-A | — | — | 2007-04-26 | — | — | JP | claimed |
| EP-1689403-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-16 | — | — | EP | claimed |
| US-20050282809-A1 | Heteroaryl-hydrazone compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | claimed |
| WO-2005046604-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | claimed |
| US-20210140945-A1 | METHODS OF TREATING NEUROLOGICAL DISEASES AND DISORDERS | MADRIGAL PHARMACEUTICALS INC (US) | 2021-05-13 | — | — | US | disclosed |
| US-20180217130-A1 | COMPOSITIONS AND METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | MADRIGAL PHARMACEUTICALS INC (US) | 2018-08-02 | — | — | US | disclosed |
| US-9910031-B2 | Compositions and methods for modulating c-Rel-dependent cytokine production | MADRIGAL PHARMACEUTICALS, INC. (US) | 2018-03-06 | — | — | US | disclosed |
| US-20160003804-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION | ACADIA WOODS PARTNERS, LLC | 2016-01-07 | — | — | US | disclosed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20120208203-A1 | COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION | SYNTA PHARMACEUTICALS CORP. (US) | 2012-08-16 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1689403-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-16 | — | — | EP | disclosed |
| EP-1682682-A2 | COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION | Synta Pharmaceuticals Corporation (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050282232-A1 | Compositions and methods for modulating c-Rel-dependent cytokine production | SYNTA PHARMACEUTICALS CORP. | 2005-12-22 | — | — | US | disclosed |
| US-20050282809-A1 | Heteroaryl-hydrazone compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | disclosed |
| WO-2005046619-A2 | COMPOSITIONS AND METHODS FOR MODULATING C-REL-DEPENDENT CYTOKINE PRODUCTION | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005046604-A2 | HETEROARYL-HYDRAZONE COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | TYK2 2464/4885SYK 737/4885IRAK4 660/4885 |
| US-20050282809-A1 | Heteroaryl-hydrazone compounds | MMP12, IL1RN, CASP12 | TYK2 3469/4885SYK 3362/4885IRAK4 639/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | TYK2 2464/4885SYK 737/4885IRAK4 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.